Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Duckhorn (NAPA) to be acquired by Butterfly Equity in $1.95B all-cash deal, with shares jumping over 100% premarket.

Lawmakers on Tuesday questioned the maker of popular weight loss drugs Ozempic and Wegovy during a Senate committee hearing focused on what Sen. Bernie Sanders called "outrageously high" prices ...

Lars Fruergaard Jørgensen, Novo Nordisk’s CEO, began his testimony by describing the company’s decades-long work developing semaglutide, the active ingredient in Ozempic and Wegovy ...

Senators contend the cost of the life saving drug is too high for many patients. Senators grilled Novo Nordisk CEO Lars Jørgensen Tuesday at a hearing over the costs of Ozempic, Wegovy and ...

Half a century of advances in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic – so what was that journey like for the scientists involved? Joel Habener of ...